Microsatellite Instability in the Tumor Microenvironment: The Role of Inflammation and the Microbiome

Elizabeth Vargas-Castellanos1, Andrés Rincón-Riveros2

  • 1Hospital Universitario Mayor-Mederi, Universidad del Rosario, Bogotá, Colombia.

Cancer Medicine
|April 15, 2025
PubMed
Abstract

Insights

The microbiome significantly impacts cancer development in microsatellite instability (MSI) tumors. Modulating gut bacteria may improve responses to cancer therapies like immune checkpoint inhibitors (ICIs).

Area of Science:

  • Oncology
  • Microbiology
  • Genomics

Background:

  • Microsatellite instability (MSI), a DNA mismatch repair (MMR) deficiency, drives genomic instability and cancer risk.
  • The tumor microenvironment (TME) and the microbiome are critical factors in MSI-driven tumorigenesis.

Purpose of the Study:

  • To review the literature on the relationship between MSI, the microbiome, and cancer.
  • To focus on how microbial dysbiosis affects the TME in MSI cancers.

Main Methods:

  • Comprehensive literature review.
  • Analysis of the impact of microbial dysbiosis on the tumor microenvironment.

Main Results:

  • MSI-high tumors show increased immune cell infiltration due to neoantigens.
  • Immune evasion mechanisms and pathobionts (e.g., Fusobacterium nucleatum) promote inflammation and oxidative stress in the TME.
  • Specific bacteria contribute to MSI by producing genotoxins.

Conclusions:

  • The microbiome plays a crucial role in MSI-driven cancer.
  • Microbiota modulation (FMT, probiotics, diet) may enhance immune checkpoint inhibitor (ICI) efficacy.
  • Further research in cancer pharmacomicrobiomics is needed for personalized cancer treatments.